scholarly journals Management of male breast cancer

2011 ◽  
pp. 44-52
Author(s):  
Nikolay V. Dimitro v ◽  
Sunil Nagpal ◽  
Shalini Chitneni
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Male Breast Cancer ◽  
Randomized Clinical Trials ◽  
Treatment Options ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Treatment Modalities ◽  
Lack Of Information ◽  
Low Incidence

The management of male breast cancer is still under discussion due to lack of information from prospective, randomized clinical trials and low incidence of this disease. Current management is based largely on extrapolation from data related to treatment of female breast cancer. Over the last two decades, several review articles have discussed mainly retrospective and anecdotal data related to hormonal and chemotherapy treatment modalities. In this review, we present the most recent information and future considerations related to the management of male breast cancer. In addition to the conventional treatment options we will discuss the possible role of targeted therapy. Establishing a national or global registry for male breast cancer will provide more precise information about the natural history of the disease and will facilitate the design and execution of prospective, randomized multicenter clinical trials.

Male breast cancer: Prognostic factors evaluation in a 35-year service

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11618-e11618
Author(s):  
R. D. Botan ◽  
M. N. Alvares ◽  
A. Hassan
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Prognostic Factors ◽  
Male Breast Cancer ◽  
Survival Curve ◽  
Local Treatment ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Breast Cancer Patients ◽  
Female Breast

e11618 Background: Treatment for male breast cancer is based on the results of large clinical trials for female breast cancer. Although peculiar differences do exist between men and women, very little is known about the prognostic factors in male breast cancer, even though female breast cancer practical conducts are widely used in male breast cancer. The rarity of this condition makes very difficult to produce randomized trials. Methods: This study is populational and epidemiological and evaluated male breast cancer patients from January 1974 to December 2001 about its prognostic characteristics. Data were collected retrospectively and the sample has been described using descriptive statistics methods. Survival curve was built using Kaplan-Meier method. Staging system was standardized as in the sixth edition of American Joint Committee on Cancer, independently on when the diagnose was made. Due to differences throughtout 35 years on therapeutic on breast cancer, treatment options were categorized in groups to make the survival evaluation possible. Results: From 45 patients with male breast cancer, 91% presented ductal histology, 26% were negative axillary, 9.1% were T1, 25% were T2, 4.5% were T3, 50% were T4 and 12.12% presented with distant metastasis at diagnose. Seventy nine percent were submitted to radical local treatment, while 34% had not been submitted to any kind of systemic treatment (neoadjuvant, adjuvant e hormone therapy). Forty percent of patients have not presented distant recurrence, while 58.3% have not presented local recurrence. A median survival of 126 months has been observed to the analyzed population, ranging from 69–182 months. Five-year survival was 72% and 10-year survival was 54%. These data agreed with the available data in the published literature. Conclusions: Male breast cancer appears to behave biologically and clinically very similar to female breast cancer, but differences do exist and need to be elucidated. Randomized multi-center clinical trials become necessary, as systematic reviews, to build higher statistic power studies. No significant financial relationships to disclose.

scholarly journals Primary Male Breast Cancer: Analysis of Eight Cases and Review of Literature

1970 ◽  
Vol 25 (1) ◽  
pp. 18-22
Author(s):  
JU Ahmed ◽  
MM Hussain
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Surgical Excision ◽  
Duct Cell ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Biological Behavior ◽  
Treatment Modalities ◽  
Duration Of Symptoms ◽  
Primary Male

This is a hospital based retrospective study with 8 cases of newly diagnosed primary male breast cancer. Among 413 cases of breast cancer of both male and females, treated between 1988 to 2002 at Chittagong, eight were males. The incidence is 1.94%. The mean age of diagnosis is 50.13 years, which is later than females. A breast mass was the earliest, most important symptom. The duration of symptoms before treatment ranged from few weeks to years. Male breast cancer is of the same common pathologic types as in females that is 75% patients had duct cell carcinoma. The rarity of the tumor hinders the study of its biological behavior and etiology, which in consequence, are still not well understood. As with the female breast cancer, surgical excision followed by adjuvant CT, RT, hormone therapy are the treatment modalities. (J Bangladesh Coll Phys Surg 2007; 25 : 18-22)

Outcomes of male breast cancer in the United States: A SEER database analysis from 1973 to 2008.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1586-1586 ◽  
Author(s):  
Akm Mosharraf Hossain ◽  
Ravi Kiran Bobba ◽  
Carl G. Kardinal ◽  
Carl Freter
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
The United States ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Treatment Modalities ◽  
Seer Database ◽  
Asian Patients ◽  
Hormone Receptor Positive ◽  
Over Time

1586 Background: Male breast cancer (MBC) is rare compared to female breast cancer (FBC). There has been no systemic study to examine the epidemiology of MBC in USA in the past decade. Methods: We examined 6,157 cases of MBC reported in SEER database from 1973-2008 (released 2011). We performed rate, frequency and survival sessions to examine age, sex, stage, grade, treatment modalities and survival using the SEER*Stat Software 7.0.5. These variables were compared with that of 877,885 FBC cases reported in SEER 1973-2008. Results: The incidence rate was 1.3 (MBC) and 124 (FBC) per 100,000, respectively. Median age of diagnosis was higher in MBC compared to FBC (72 vs. 61 yrs. P<0.001). 18% of MBC were seen at age less than 60 years compared to 32% in FBC (p<0.001). FBC tend to be more hormone receptor positive (74% vs. 61%; p<0.001). There were 5,145 Caucasians (WH), 701 African Americans (AA), 258 Hispanics and 42 Asian patients. Stage III and IV, Grade III and IV histologies were more common in MBC. Staging and Grading did not differ among the different ethnicities except for Grade IV histology in AA 19%, Asians 20% when compared to WH 13% (p<0.001). Treatment modalities included, surgery (MBC 78% vs. FBC 93%; p<0.001), chemotherapy (MBC 82% vs. FBC 43%; p<0.001) and radiation therapy (MBC 19% vs. 36% FBC; p<0.001). Treatment modalities were similar among WH and AA. Survival was higher in FBC compared to MBC (table) but improved over time in MBC. AA and Asians had lower 1-5 year survival compared to WH. Conclusions: MBC presents at a later age, higher stage and grade, predominantly requiring chemotherapy with an overall poor survival compared to FBC. But 1-5 year survival improved over time in MBC. This can be explained by early diagnosis, better treatment and other factors. Further studies should be performed in this regard. [Table: see text]

scholarly journals Assessment of Knowledge and Attitude Regarding Female and Male Breast Cancer among Adults of South India

2021 ◽  
pp. 13-20
Author(s):  
Anwitha Johns ◽  
Satish Kumar B P ◽  
Lavanya P R
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Female Breast Cancer ◽  
Incidence Rates ◽  
Male Breast ◽  
Basic Knowledge ◽  
Nominal Data ◽  
Female Breast ◽  
South Indian ◽  
Knowledge And Attitude

Background & Objectives: Breast cancer is the second leading reason for cancer death in women. Incidence rates of male breast cancer have increased by 0.2- 1% per year. The lack of knowledge and awareness of male breast cancer leads to its detection at a late stage in men. This study is to assess the knowledge and attitude of south Indian adults towards male and female breast cancer. Methods: To assess the knowledge and attitude of adults on breast cancer, a questionnaire regarding basic knowledge and attitudes was formulated using Google forms. Numbers and percentages were formed to review categorical and nominal data. Chi-square (χ2) test was used for the comparison between the awareness of female breast cancer and male breast cancer. P < 0.05 was set as the level of significance.

Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report and literature overview

2020 ◽  
pp. 030089162097698
Author(s):  
Emma Zattarin ◽  
Francesca Ligorio ◽  
Federico Nichetti ◽  
Giulia Bianchi ◽  
Giuseppe Capri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Case Report ◽  
Male Breast Cancer ◽  
Clinical Case ◽  
Previous Treatment ◽  
Male Breast ◽  
Cancer Case ◽  
Heavily Pretreated ◽  
Breast Cancer In Men

Introduction: Breast cancer in men is less common than in women and treatment recommendations are often derived from clinical trials exclusively involving women. Data on efficacy of CDK 4/6 inhibitors, which are the mainstay of treatment for hormone receptor–positive/HER2-negative advanced breast cancer, are lacking in male patients. Case report: We present a clinical case of prolonged benefit from palbociclib in combination with letrozole and LHRH analogue in a man who had previously been treated with six lines of endocrine therapies and chemotherapy regimens but was still in excellent clinical condition. Conclusions: This clinical case demonstrates that male breast cancer stands out as an endocrine-sensitive disease, which could potentially benefit from CDK 4/6 inhibitors in combination with endocrine agents even in very heavily pretreated settings of disease, underscoring both the importance of an accurate selection of patients for later treatment lines, taking into account disease history and previous treatment responses, and the peculiarity of breast cancer in men, which deserves dedicated clinical trials to tailor future recommendations.

Is Male Breast Cancer Similar or Different than Female Breast Cancer?

2004 ◽  
Vol 83 (1) ◽  
pp. 77-86 ◽  
Author(s):  
William F. Anderson ◽  
Michelle D. Althuis ◽  
Louise A. Brinton ◽  
Susan S. Devesa
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Female Breast

scholarly journals Evaluation of General, Pathological, and Radiological Features of Male Breast Cancer

2020 ◽  
Vol 17 (3) ◽  
Author(s):  
Fariba Zarei ◽  
Fereshte Bagheri ◽  
Amin Dehdashtian ◽  
Majid Akrami
Keyword(s):  
Breast Cancer ◽  
Survival Time ◽  
Male Breast Cancer ◽  
Medical Records ◽  
Male Breast ◽  
Treatment Modalities ◽  
Time Interval ◽  
Number Of Patients ◽  
History Of

Background: Male breast cancer (MBC) is an infrequent disease and a scarcely researched topic. Since the incidence of male breast cancer is increasing and so far, management advices have been concluded from results of trials in female patients, there has been a growing interest in this field of research. Objectives: In this study, we aimed to evaluate the general, radiological and pathological features of MBC patients. Patients and Methods: We retrospectively reviewed the medical records of MBC patients who had been referred to breast clinic, Shahid Motahari in Shiraz, Iran, between 2005 and 2018. Data regarding general characteristics of patients such as demographic information, age, and also past history of any cancer, family history of breast cancer, mammogram and ultrasound findings, stage, size and location of tumor, histopathology of tumor, metastasis, treatment modalities and follow-up time were attained by reviewing medical records. Results: Fifty-one patients with MBC were included with the mean age of 58.4 years. Invasive ductal carcinoma was the most prevalent pathologic type. By use of the Kaplan Meier survival estimate, survival probability of patients for each time interval after diagnosis was calculated. There was a decline over time until about 85 months after diagnosis when it reached a plateau state above 50%. Age, human epidermal growth factor receptor 2 (HER2) and metastasis showed to lower the survival time by increasing the hazard ratio. Only 13 patients had mammography and 22 had an ultrasound, which are less than 50% of the total number of patients. Conclusions: This study showed that there is still unfulfilled need to evaluate MBC in order to find the best management guidelines such as screening in high risk populations, diagnosis, treatment, and follow-up. Risk factor evaluation, survival time, and diagnostic radiologic modalities have not been well assessed in MBC so far.

Examining racial disparities in male breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6555-6555
Author(s):  
Elizabeth Shurell Linehan ◽  
Navendu D. Samant ◽  
Juleon W Rabbani
Keyword(s):  
Breast Cancer ◽  
Racial Disparities ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Breast Cancer Patients ◽  
Female Breast ◽  
Mean Time ◽  
Related Mortality

6555 Background: Male breast cancer (MBC) accounts for approximately 1% of all breast cancers. Racial disparities have not been examined in MBC. Methods: Within a large, integrated health delivery system, all adult female and male patients who were diagnosed with breast cancer from 01-01-2010 to 12-31-2018 were examined. Bivariate analysis was performed to examine clinical and demographic factors associated with breast cancer-related mortality. We conducted more detailed chart review in the MBC-only group (data period 01-01-2010 to 12-31-2019) to assess the mean time to treatment (from diagnosis to surgery, surgery to chemotherapy, and surgery to radiation) stratified by race using bivariate (t-test, one way ANOVA) analyses. Results: 32,848 female breast cancer and 226 MBC patients were evaluated; MBC patients represented 0.63% of all breast cancer patients. Between males and females, there was no statistically significant difference in race, with an overall distribution of 62% White, 19% Asian, 8% Black, and 11% Hispanic. To our knowledge, this is the largest and most racially diverse sample of MBC patients to date. MBC patients at diagnosis were significantly older (p <.0001), more obese (p < 0.0018), and sicker according to the Charlson Comorbidity Index (CCI) (p < 0.0001) compared to female breast cancer patients. Males were more likely to be diagnosed at an advanced stage (19.2%) compared to females (12.5%) (p = 0.0037). With a mean follow up of 5 years, overall mortality was statistically significantly worse in MBC (23.0%) compared to female breast cancer patients (12.0%) (p < 0.0001). Furthermore, breast cancer-related mortality was significantly higher in males (8.1%) than in females (4.5%) (p = 0.0124). In the MBC-only analysis, stage at diagnosis was not influenced by patient race. Asian and White MBC patients had the shortest mean time from diagnosis to surgery (27 and 29 days, respectively), with Hispanic MBC patients experiencing the longest time to surgery (46 days). Black MBC patients experienced the shortest mean time to chemotherapy after surgery (39 days), whereas Asian MBC patients experienced the longest time to chemotherapy (50 days). In survivorship, Black and Asian patients were least likely to undergo screening mammography (33.3%, and 43.3%, respectively), compared to 52% of White and 50% of Hispanic MBC patients. Ultimately, 13% of Asian and 11% of Hispanic MBC patients died of breast cancer, compared to 6.7% of Black and 6.2% of White MBC patients. Conclusions: While we found no statistically significant differences in mortality by race among MBC patients, our findings indicate that non-white patients had longer time to treatments, less survivorship screening, and worse disease related mortality than their white counterparts. Future study can elucidate these racial inequalities, enabling more equitable breast cancer treatment among patient subgroups.

Sign in / Sign up

Export Citation Format

Share Document